查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971319

脑膜炎双球菌疫苗市场－全球产业规模、份额、趋势、机会、预测：按类型、年龄层、地区和竞争格局划分，2021-2031年

Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Conjugate, Polysaccharide, Combination, Others), By Age Group (Infant, Children & Adult), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球脑膜炎双球菌疫苗市场预计将从 2025 年的 43.8 亿美元成长到 2031 年的 61.8 亿美元，复合年增长率为 5.91%。

这些生物製药对于建立针对脑膜炎双球菌的免疫力、预防脑膜炎和败血症等严重侵袭性疾病至关重要。市场成长的主要驱动力是这些疫苗被纳入国家免疫规划，以及对前往流行地区（例如倡议和副朝）的旅客实施严格的监管要求。此外，政府支持的青少年补种疫苗计画以及私部门对B群脑膜炎双球菌疫苗的日益普及也促进了收入成长。

市场概览
预测期 2027-2031
市场规模：2025年 43.8亿美元
市场规模：2031年 61.8亿美元
复合年增长率：2026-2031年 5.91%
成长最快的细分市场 复杂类型
最大的市场 北美洲

然而，由于疫苗研发成本高以及低收入地区配送所需的复杂低温运输物流等因素，疫苗市场面临许多障碍。儘管这些经济和物流障碍限制了疫苗的普及，但不断上升的感染率凸显了公共卫生问题的迫切性。例如，根据美国疾病管制与预防中心（CDC）的报告，2024年美国确诊和估计的病菌感染疾病病例数将达到503例，这是自2013年以来的最高年度数字。儘管供应链的复杂性和定价挑战阻碍了全球市场渗透，但这些数据表明，儘管供应链复杂且价格高昂，但仍迫切需要有效的疫苗。

市场驱动因素

推动市场发展的因素之一是近期非洲和欧洲侵袭性脑膜炎双球菌病菌感染激增，迫使各国政府加强监测并实施紧急免疫措施。这次疫情反弹对先前被认为已控制的地区造成了重大影响，因此需要即时采购疫苗以遏制疫情蔓延。根据英国卫生与安全局 (UKHSA) 2025 年 11 月发布的公告，2024-2025 年英格兰确诊的侵袭性病菌感染病例数从上年度的340 例增至 378 例。为因应这些流行病学变化，各国正在扩大免疫接种计画并推动接触者追踪宣传活动，随着当局集中精力控制疫情蔓延，疫苗订单也不断增加。

同时，随着先进的多价结合疫苗的问世，市场也不断发展，只需一剂即可提供多种血清型的保护。这些创新简化了大规模免疫接种的物流，尤其是在需要严格低温运输管理的高风险地区。 2025年4月，全球疫苗免疫联盟（Gavi）迎来了一个重要的里程碑：尼日利亚获得了超过100万剂新型五价脑膜炎双球菌结合疫苗（Men5CV），用于应对严重的疫情爆发。这种向综合配方发展的趋势正在提升主要生产商的财务表现。例如，葛兰素史克（GSK）在2025年10月报告称，其脑膜炎疫苗第三季销售额达到5亿英镑，年增5%，这主要得益于强劲的国际需求。

市场挑战

脑膜炎双球菌疫苗的全球市场受到疫苗研发高成本和维持低温运输完整性的物流挑战的严重限制。製造商在研发和生产过程中投入大量资金，导致疫苗价格往往超出发展中国家的医疗预算。运输过程中严格的温度控制要求进一步加剧了这种经济差距，使得在缺乏可靠基础设施的地区分发疫苗变得异常困难。因此，该市场难以覆盖撒哈拉以南非洲的高需求地区，其商业性可行性主要局限于疾病发生率低的富裕地区。

由于无法以可负担的价格建立稳定的供应链，市场被迫依赖被动的、由捐助者资助的紧急措施，而非永续的商业管道。近期的一些营运统计数据凸显了这种被动应对方式的优势。根据全球疫苗免疫联盟（Gavi）统计，到2024年底，16个国家已动用了68次多价脑膜炎双球菌疫苗紧急储备，需要运送超过3,440万剂疫苗来控制疫情。这凸显了资金和物流方面的限制如何将市场活动局限于零星的紧急应变，阻碍了市场向更广泛、更稳定的收入模式转型。

市场趋势

五价脑膜炎双球菌疫苗（MenABCWY）的推广正在改变市场格局。这种疫苗将针对五种血清型的保护整合到单一的免疫接种方案中，有效解决了青少年时期多剂次接种依从性下降的问题。这一趋势在美国等已开发市场尤为显着，领先的製药公司正在获得核准，将B型脑膜炎球菌成分与标准B型脑膜炎双球菌（MenACWY）结合疫苗相结合。这项转变的关键进展是美国食品药物管理局（FDA）于2025年2月核准了PenMenV，这是一种适用于10至25岁族群的新型五点疫苗。葛兰素史克（GSK）报告称，这些组合产品最大限度地减少了所需的接种剂量，并有望提高B型脑膜炎双球菌的疫苗接种率。由于复杂的接种通讯协定，B型脑膜炎双球菌的接种率历来都低于其他血清群。

同时，将B群脑膜炎双球菌疫苗纳入国家免疫规划是一项重大的政策转变，使这些产品从民营市场选择转变为政府强制必需品。欧洲卫生当局日益重视婴幼儿的普遍疫苗接种，以预防侵袭性脑膜炎双球菌病菌感染的严重后果，并透过公共采购确保市场规模。法国卫生署于2025年1月决定强制所有婴儿接种B群脑膜炎双球菌疫苗，并制定了3、5和12个月大的标准接种程序，这清楚地反映了这项政策进展。此类监管变化将要求生产商调整其供应链以适应国家竞标，从而在确保稳定需求的同时，消除先前限制高风险儿童群体获得疫苗的经济障碍。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球脑膜炎双球菌疫苗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（结合型、多醣型、混合型、其他）
    • 依年龄组别（婴儿、儿童、成人）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美脑膜炎双球菌疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲脑膜炎双球菌疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区脑膜炎双球菌疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲脑膜炎双球菌疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲脑膜炎双球菌疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球脑膜炎双球菌疫苗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Sanofi SA
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Pfizer, Inc.
  • Walwax Biotechnology Co., Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24314

The Global Meningococcal Vaccines Market is projected to expand from USD 4.38 Billion in 2025 to USD 6.18 Billion by 2031, reflecting a compound annual growth rate of 5.91%. These biological preparations are crucial for establishing immunity against Neisseria meningitidis bacteria, thereby preventing severe invasive conditions like meningitis and septicemia. The market's growth is primarily fuelled by the integration of these vaccines into national immunization programs and strict regulatory requirements for travelers visiting endemic areas, such as pilgrims performing Hajj and Umrah. Furthermore, revenue growth is bolstered by government-supported catch-up initiatives for adolescents and the increasing commercial adoption of Serogroup B vaccines within the private sector.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.38 Billion
Market Size 2031USD 6.18 Billion
CAGR 2026-20315.91%
Fastest Growing SegmentCombination
Largest MarketNorth America

However, the market faces significant obstacles due to the substantial costs associated with vaccine development and the intricate cold-chain logistics necessary for distribution in low-income regions. These economic and logistical barriers restrict accessibility, even as rising infection rates underscore a critical public health need. For example, the Centers for Disease Control and Prevention reported 503 confirmed and probable cases of meningococcal disease in the United States in 2024, the highest annual figure since 2013. This data emphasizes the urgent demand for effective vaccines, even as supply chain complexities and pricing challenges hinder broader global market penetration.

Market Driver

A major catalyst for the market is the recent increase in invasive meningococcal disease outbreaks across Africa and Europe, which is urging governments to strengthen surveillance and implement emergency vaccination measures. This resurgence is notably affecting areas where the disease was previously thought to be managed, necessitating immediate vaccine procurement to halt transmission. According to the UK Health Security Agency in November 2025, confirmed invasive meningococcal disease cases in England increased to 378 during the 2024-25 period, up from 340 the prior year. Such epidemiological changes are prompting the expansion of national immunization schedules and catch-up campaigns, resulting in higher vaccine order volumes as authorities focus on containment.

Concurrently, the market is evolving through the distribution of advanced multivalent conjugate vaccines, which provide protection against multiple serogroups in a single dose. These innovations simplify the logistics of mass immunization, especially in high-risk areas with challenging cold-chain requirements. A significant milestone was noted by Gavi, the Vaccine Alliance, in April 2025, when Nigeria received over one million doses of the new pentavalent meningococcal conjugate vaccine (Men5CV) to fight a severe outbreak. This trend toward comprehensive formulations is improving the financial results of leading manufacturers; for instance, GSK reported in October 2025 that its meningitis vaccine sales reached £0.5 billion in the third quarter, a 5% rise driven by robust international demand.

Market Challenge

The expansion of the Global Meningococcal Vaccines Market is heavily restricted by the high costs of vaccine development coupled with the logistical difficulties of maintaining cold-chain integrity. Manufacturers face substantial expenses during research and production, leading to pricing structures that often exceed the healthcare budgets of developing nations. This economic gap is worsened by the need for strict temperature controls during transport, making distribution impractical in areas without reliable infrastructure. As a result, the market struggles to reach high-demand populations in Sub-Saharan Africa, limiting commercial viability primarily to wealthier regions with lower disease incidence.

This failure to establish affordable, routine supply chains compels the market to depend on reactive, donor-funded emergency measures rather than sustainable commercial channels. The dominance of this reactive approach is highlighted by recent operational statistics. According to Gavi, the Vaccine Alliance, by the end of 2024, the emergency stockpile for multivalent meningococcal vaccines was utilized 68 times by 16 countries, requiring the shipment of over 34.4 million doses to manage outbreaks. This underscores how financial and logistical constraints effectively limit market activity to sporadic emergency responses, hindering the shift toward a broader and more stable revenue model.

Market Trends

The commercial landscape is being transformed by the shift toward Pentavalent MenABCWY combination vaccines, which consolidate protection against five serogroups into a single regimen to address low compliance with multi-injection schedules among adolescents. This trend is especially strong in developed markets such as the United States, where pharmaceutical leaders are achieving regulatory approvals for formulations combining standard MenACWY conjugates with Serogroup B components. A key development in this transition was reported by GSK in February 2025, when the US Food and Drug Administration (FDA) approved Penmenvy, a new pentavalent vaccine for individuals aged 10 to 25. By minimizing the number of required injections, these combination products are anticipated to boost coverage rates for Serogroup B, which has historically trailed other serogroups due to complex administration protocols.

At the same time, the integration of Serogroup B vaccines into national immunization schedules represents a significant policy shift, elevating these products from private-market options to government-mandated essentials. European health authorities are increasingly prioritizing universal infant coverage to prevent the severe consequences of invasive meningococcal disease, thereby securing market volume through public procurement. This policy evolution was illustrated in January 2025, when the Ministry of Health in France made vaccination against meningococcal serogroup B mandatory for all infants, establishing a standard schedule with doses at 3, 5, and 12 months. Such regulatory changes force manufacturers to align their supply chains with national tenders, ensuring consistent demand while eliminating financial barriers that previously limited access for high-risk pediatric populations.

Key Market Players

  • Sanofi S.A.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Pfizer, Inc.
  • Walwax Biotechnology Co., Ltd

Report Scope

In this report, the Global Meningococcal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Meningococcal Vaccines Market, By Type

  • Conjugate
  • Polysaccharide
  • Combination
  • Others

Meningococcal Vaccines Market, By Age Group

  • Infant
  • Children & Adult

Meningococcal Vaccines Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Meningococcal Vaccines Market.

Available Customizations:

Global Meningococcal Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Meningococcal Vaccines Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Conjugate, Polysaccharide, Combination, Others)
    • 5.2.2. By Age Group (Infant, Children & Adult)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Meningococcal Vaccines Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Age Group
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Meningococcal Vaccines Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Age Group
    • 6.3.2. Canada Meningococcal Vaccines Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Age Group
    • 6.3.3. Mexico Meningococcal Vaccines Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Age Group

7. Europe Meningococcal Vaccines Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Age Group
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Meningococcal Vaccines Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Age Group
    • 7.3.2. France Meningococcal Vaccines Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Age Group
    • 7.3.3. United Kingdom Meningococcal Vaccines Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Age Group
    • 7.3.4. Italy Meningococcal Vaccines Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Age Group
    • 7.3.5. Spain Meningococcal Vaccines Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Age Group

8. Asia Pacific Meningococcal Vaccines Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Age Group
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Meningococcal Vaccines Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Age Group
    • 8.3.2. India Meningococcal Vaccines Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Age Group
    • 8.3.3. Japan Meningococcal Vaccines Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Age Group
    • 8.3.4. South Korea Meningococcal Vaccines Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Age Group
    • 8.3.5. Australia Meningococcal Vaccines Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Age Group

9. Middle East & Africa Meningococcal Vaccines Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Age Group
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Meningococcal Vaccines Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Age Group
    • 9.3.2. UAE Meningococcal Vaccines Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Age Group
    • 9.3.3. South Africa Meningococcal Vaccines Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Age Group

10. South America Meningococcal Vaccines Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Age Group
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Meningococcal Vaccines Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Age Group
    • 10.3.2. Colombia Meningococcal Vaccines Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Age Group
    • 10.3.3. Argentina Meningococcal Vaccines Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Age Group

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Meningococcal Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sanofi S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. GlaxoSmithKline plc
  • 15.4. Serum Institute of India Pvt. Ltd.
  • 15.5. Pfizer, Inc.
  • 15.6. Walwax Biotechnology Co., Ltd

16. Strategic Recommendations

17. About Us & Disclaimer